Background {#Sec1}
==========

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain or discomfort in combination with disturbed bowel habits in the absence of an identifiable cause \[[@CR1]\]. Currently, the morbidity of IBS is 7--21 % worldwide, it can occur at any age, mainly between 30 and 50 years \[[@CR2], [@CR3]\]. Of all types, diarrhea-predominant irritable bowel syndrome (IBS-D) is the most common subtype \[[@CR4]\]. IBS has gained attention because it significantly reduces people's quality of life (QOL) and influences medical resources and social economy \[[@CR5], [@CR6]\].

The pathogenesis of IBS is unclear. It is probably related to visceral hypersensitivity, brain--gut regulation dysfunction, intestinal infection and inflammation, and psychological factors \[[@CR2], [@CR7]\]. The current treatment for IBS is to remove the inducing factors and relieve the symptoms. However, the poor efficacy and the side effects from long-term drug use have forced patients to seek alternative interventions \[[@CR8], [@CR9]\]. In recent years, physicians as well as patients are more interested in complementary and alternative medicine including acupuncture and moxibustion \[[@CR10], [@CR11]\]. While much less popular than acupuncture, moxibustion exerts its effects through warm stimulation caused by burning moxa on the acupuncture points. Mild-warm moxibustion is a therapy in which a burning moxa stick is pointed to a moxibustion site (usually an acupuncture point) at a distance to make the patient have a warm sensation but without any burning pain. Because of its low cost and easy application, moxibustion is often used to treat gastrointestinal diseases. However, its efficacy on IBS has not been confirmed. Previous trials on the treatment of IBS with moxibustion were often lack of strict control of randomization and related risk of bias, which makes the conclusions less convincing \[[@CR12]\]. A recent randomized controlled trial on herb-partitioned moxibustion for IBS also failed to fully confirm its effectiveness, and the results still need to be verified \[[@CR13]\].

Therefore, a multi-center, parallel-group, 1:1 allocation, randomized, single-blind and placebo-controlled trial has been designed in this study. The aim is to evaluate the clinical efficacy and safety of moxibustion in patients with IBS-D. The results may provide evidence for the clinical use of moxibustion in patients with IBS-D.

Methods/design {#Sec2}
==============

Study design {#Sec3}
------------

This study is a multi-center, randomized, single-blind and placebo-controlled clinical trial. All the subjects will be enrolled according to the ROME III IBS-D diagnostic criteria \[[@CR14]\]. The flowchart of the trial is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram of study design

Patients {#Sec4}
--------

All the 104 cases will be recruited from the following three research centers: the Bowel Disease Clinic of the Shanghai Research Institute of Acupuncture and Meridian; the Department of Acupuncture-Moxibustion of the Yueyang Integrated Chinese and Western Medicine Hospital at the Shanghai University of Traditional Chinese Medicine (TCM); and the Department of Acupuncture-Moxibustion of the Shanghai TCM-Integrated Hospital, Shanghai University of TCM. Recruitment notices were released on TV, newspapers, and magazines. Also, recruiting posters were posted in the community and public places nearby to ensure enough subjects.

Sample size calculation {#Sec5}
-----------------------

Previous studies showed that the effective rates of the mild-warm moxibustion group and the placebo group were 88.7 % \[[@CR15]\] and 62 % \[[@CR16]\], respectively. Based on these values, the sample size in this study is estimated as follows:$$\documentclass[12pt]{minimal}
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The significant level is 0.05; the power of test is 1 − *β* = 0.9, *k* = 1; and the sample loss rate is 15 %. The required sample size is 52 by calculation, and no less than 104 cases should be included in the two groups.

Randomization {#Sec6}
-------------

In this study, random numbers are generated by SPSS and kept by a clinical research coordinator who has no contact with the patients. The allocation will be concealed in sequentially numbered, opaque, sealed envelopes containing the randomization assignments. An eligible subject who meets the inclusion criteria will sign the informed consent. Researchers in a research center will use a random number and grouping information sent by telephone, text message, or e-mail from the clinical research coordinator, and assign the subject into moxibustion or placebo moxibustion groups.

Blinding {#Sec7}
--------

The practitioners could not be blinded due to the unique nature of moxibustion treatments. The patients are blinded to the treatment. They are kept in individual isolated rooms, avoiding communication among them. Furthermore, Researchers responsible for data collection, analysis, and statistics have no information about grouping and treatment.

Eligibility {#Sec8}
-----------

Inclusion criteria:Patients who are enrolled according to the ROME III IBS-D diagnostic criteriaPatients aged between 18 and 65 yearsPatients who have signed informed consent

Exclusion criteria:Patients who present with intestinal organic disordersPatients who have been administered drugs for treating IBS-D or other drugs that may influence the trialPatients who have a severe disease of the heart, brain, lung, liver, kidney, or hematopoietic systemPatients who are diagnosed with a psychiatric disorderWomen in pregnancy or nursingPatients who have a history of abdominal surgeryPatients who have been treated by acupuncture and moxibustion

Interventions {#Sec9}
-------------

### Treatment group {#Sec10}

For mild-warm moxibustion treatment, bilateral ST25 and ST36 points are used (reference for PRC National Standard GB/T 12346--2006) \[[@CR17]\]. A moxa stick (diameter 3 cm) is ignited and positioned with a supporting device so that the tip of the moxa stick is 3--5 cm above the acupuncture point. The temperature of the acupuncture point is monitored with an infrared thermometer (Fluke 62, USA) and maintained at 43 ± 1 °C to make the subject feel warm without any burning pain. The treatment lasts for 30 min each time, three times a week for 6 weeks (18 times). After the treatment, follow-ups are made at weeks 12 and 18.

### Control group {#Sec11}

For the placebo moxibustion group, the same acupuncture points as the treatment group are used. The same type of moxa stick is ignited but kept 8--10 cm above the acupuncture point. The temperature of the acupuncture point is similarly monitored but maintained at 37 ± 1 °C so that the subjects do not to feel warm at the points. The treatment cycle and follow-up time are the same as the treatment group.

Outcome measurements {#Sec12}
--------------------

### Primary outcome {#Sec13}

#### Adequate relief {#FPar1}

Adequate relief (AR) is used to evaluate the degree of alleviation of IBS symptoms, with relief of abdominal pain or abdominal discomfort as the criterion. During the treatment and follow-up, the patients evaluate themselves once every week. The primary endpoint is set at the end of the treatment (week 6), and the statistics are also performed during follow-ups (weeks 12 and 18) for efficacy duration assessment. "Yes" is defined as positive symptom improvements in more than 3 weeks during the 6-week period; "no" is defined as positive symptom improvements in less than 3 weeks \[[@CR18]\]. The indicator has been applied in several studies \[[@CR19], [@CR20]\] and was found to have significant correlations with intestinal function and QOL \[[@CR21]\].

### Secondary outcomes {#Sec14}

#### IBS Symptom severity score {#FPar2}

IBS symptom severity score (SSS) \[[@CR22]\] is used to evaluate the degree of severity of IBS-D in the patients. A total score of 500 is calculated from abdominal pain degree, abdominal pain frequency, abdominal distension degree, defecation satisfaction, and influence on life. If the score is lower than 75, the patient is considered to be in remission. The mild, moderate, and severe boundary values are 75--175, 175--300, and above 300, respectively. The effectiveness, reliability, and sensitivity of IBS SSS to treatment are verified.

#### Bristol stool form scale {#FPar3}

Grading standard in the Bristol stool form scale (BSS) \[[@CR23]\] is employed to record stool characteristics of the patients with IBS-D in this study. The scale is a visual descriptive figure reflecting gastrointestinal transit time. The total score of the scale ranges from 1 to 7 according to the 1--7 types (from constipation to diarrhea) of stool characteristics.

#### Irritable bowel syndrome quality-of-life questionnaire {#FPar4}

Irritable bowel syndrome quality-of-life questionnaire (IBS-QOL) is a specialized scale developed by Patrick et al. \[[@CR24]\] for patients with IBS. It is composed of 34 items of self-assessment ranging from dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, to sexual relationships, to assess QOL. The patients' QOL is measured by a 5-point linear scale, and each question has a 5-point Likert scale (score 1--5). The total score of the scale ranges from 34 to 170. The scale achieves good measurement validity.

#### Hospital anxiety and depression scale {#FPar5}

Hospital anxiety and depression scale (HADS) is used to assess the level of anxiety and depression in patients with IBS-D \[[@CR25]\]. It comprises 14 questions, with seven questions each on anxiety and depression. Each question has a 4-point Likert scale (score 0--3). The total score of the scale ranges from 0 to 42. A score greater than 8 in each subscale indicates anxiety/depression.

IBS-SSS and BSS are completed before treatment (week 0), at the end of treatment (week 6), and during follow-ups (weeks 12 and 18). IBS-QOL and HADS are completed before treatment (week 0) and at the end of treatment (week 6). All the assessments are shown in Table [1](#Tab1){ref-type="table"}.Table 1Trial flowchartItemsBefore enrolment (weeks) --4 to 0Intervention period (weeks) 1--6End of 6-week treatment (weeks)Follow-up (weeks) 7--12End of 12-week follow-up (weeks)Follow-up (weeks) 13--18End of 18-week follow-up (weeks)Recruitment×Enrolment×Inclusion criteria×Exclusion criteria×Informed consent×Basic characteristic variables×Randomization and allocation concealment×Primary outcomesAR××××××Secondary outcomesSSS××××BSS××××IBS-QOL××HADS××Safety outcome×××Statistical analysis×××

Safety outcome {#Sec15}
--------------

In this study, possible adverse events during moxibustion include skin burns, blisters, pruritus, dizziness, and respiratory symptoms. The researchers record and deal with all the adverse events (no matter whether it is relevant with moxibustion). When necessary, the researchers can decide whether the trial is terminated.

Quality control {#Sec16}
---------------

All the researchers are practicing doctors certified by the Ministry of Health of the People's Republic of China. They must have more than 5 years of clinical experience and be qualified as attending physicians. All the researchers are trained to improve consistency among subjects. The outcomes are assessed for all the subjects. The outcome measurement data are preserved in the original case report form (CRF), and supervised and checked by a qualified clinical research coordinator. The original data are recorded into the electronic medical records using a double data entry method by trained researchers, and the electronic data are consistent with the original data. To improve compliance of the subjects, each subject who completes the trial is provided a cash reward.

Data monitoring {#Sec17}
---------------

This study has set up an independent clinical trial data monitoring committee (DMC), which comprises a medical expert and two clinical research experts. The DMC verifies whether the trial follows the study design and the standard guidelines, checks research progress and the accuracy and authenticity of the CRF, and checks whether the reasons for discontinuation of subjects and adverse events have been recorded in detail in the CRF. In the case of any serious adverse events, the DMC discusses with the institutional review board and the principal investigator, and the principal investigator makes a final decision on the continuation or termination of the trial. In addition, the institutional review board also makes recommendation to the principal investigator on stopping the trial if a serious adverse event occurs.

Statistical analysis {#Sec18}
--------------------

The statisticians are responsible for coordinating research efforts, making a statistical analysis plan, and building a research database. Both intention-to-treat and per-protocol analyses are performed. The last-observation-carried-forward method is used for missing data in the intention-to-treat analysis. SPSS16.0 software is used to analyze the data. Measurement data are first tested using the normality test. Data conforming to the normal distributions are expressed as mean ± standard deviation, while data not conforming to the normal distributions are expressed as M (P25--P75). A paired *t* test or nonparametric test is used to perform intragroup comparison, and a two-sample *t* test or nonparametric test is used to perform comparison among groups. Enumeration data is expressed as a case (ratio) and analyzed using the *χ* ^2^ test. Statistic significance is defined as *p* \< 0.05.

Discussion {#Sec19}
==========

The present study assesses the efficacy and safety of mild-warm moxibustion treatment in patients with IBS-D through a multi-center, randomized, single-blind and placebo-controlled trial.

To confirm the efficacy of mild-warm moxibustion, placebo moxibustion is used as control which is included to eliminate potential placebo effect of moxibustion treatment. Methods for designing a placebo control group for mild-warm moxibustion were limited in the past. One study \[[@CR26]\] used a 0.5 cm diameter moxa cone as a placebo in a blind trial. However, this method is impractical in our research design because the moxa stick used for warm moxibustion has to be longer than 1.5 cm which is also the most widely used specification in clinical practice.

At least two conditions should be satisfied in the design of placebo-controlled moxibustion: one is that the placebo model has no specific therapeutic function, the other is that subjects cannot perceive the difference between the placebo moxibustion and the real one. It has been proved that thermal stimulation is an important factor that influences the treatment efficacy, as the heat must reach a certain level to exert the effect \[[@CR27], [@CR28]\]. In this study, we use a moxa stick of 3 cm diameter to achieve better efficacy through stimulating the acupuncture points for more heat. Due to the unique nature of moxibustion treatment, if the heat stimulus was fully shielding, the participants will not be well blinded. Therefore, we try to reduce the heat stimulation of moxibustion to a minimum, while blind to the participants. The distance of the moxa stick to the acupuncture points in the placebo control group is set to 8--10 cm, and the temperature of the acupuncture point is maintained at 37 ± 1 °C. At this temperature, the subjects will feel "lukewarm", because the temperature of human skin is between 30 and 36 °C with the average temperature at 33.5 ± 0.5 °C. In contrast, the distance of the moxa stick to the acupuncture points in the treatment group is set to 3--5 cm, so that the subjects feel warm without any burning pain. The temperature of the acupuncture point is maintained at 43 ± 1 °C, which is shown to contribute to the efficacy of moxibustion treatment \[[@CR29]\]. It is important to mention that the subjects will be enrolled with no history of acupuncture and moxibustion treatment, and are not aware of the manipulation of moxibustion. Furthermore, they will be treated in individual isolated rooms, which prevent them from communicating with each other. Hence, the environment is conducive to perform the trial.

A limitation of the trial is that the study cannot double-blind the physicians and subjects. Thus, potential subjective factors in the clinician's approach to the task and possible awareness of the subjects about the treatment they receive may lead to bias of the study.

The present protocol may demonstrate moxibustion as a safe and effective treatment for patients with IBS-D. If the goals of the study are achieved, we will provide new evidence that moxibustion may be an effective therapy for treating IBS-D. The low-cost, easy-applicable treatment will reduce the financial burden for the patients and healthcare system, relieve the medical burden of hospitals and save medical resources.

Trial status {#Sec20}
------------

The trial is currently in the recruitment phase. Participant recruitment started in April 2015, and is expected to end in December 2017.

AR

:   Adequate relief

BSS

:   Bristol stool form scale

CRF

:   Case report form

DMC

:   Data monitoring committee

HADS

:   Hospital anxiety and depression scale

IBS

:   Irritable bowel syndrome

IBS-D

:   Diarrhea-predominant irritable bowel syndrome

IBS-QOL

:   Irritable bowel syndrome quality-of-life

IBS-SSS

:   Irritable bowel syndrome symptom severity score

TCM

:   Traditional Chinese medicine

The authors would like to thank Dr Zhe Ma and Yi Wang for helping to recruit patients and Dr Lili Ma for screening of eligible subjects in this trial. The authors would also like to express appreciation to Dr Xiaoming Jin for revising the manuscript.

Funding {#FPar6}
=======

This study has been supported by the National Key Basic Research Program of China (973 program) (2015CB554501); the National Natural Science Foundation of China (81503656); the Shanghai Sailing Program (15YF1411200); and the Shanghai Municipal Health Bureau (20154Y0138).

Availability of data and material {#FPar7}
=================================

The datasets supporting the conclusions of this article are included within the article.

Authors' contributions {#FPar8}
======================

CHB, JZZ, and JML participated in the design of the study and drafted the manuscript. HRL and LYW participated in the statistical design and helped in the design of the study. SYW and YS helped to draft the manuscript. CHB, JZZ, JML, JL, ZHH, YZD and XQZ recruited participants from clinics and communities. HGW conceived the study and was the general supervisor for this research. All authors have read and approved the final manuscript.

Competing interests {#FPar9}
===================

The authors declare that they have no competing interest.

Consent for publication {#FPar10}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar11}
==========================================

The study has been approved by the Institutional Review Board of the Yueyang Hospital of Integrated Chinese and Western Medicine, affiliated with the Shanghai University of Traditional Chinese Medicine. The present research is registered in the Clinical Trials database (NCT02421627, <https://clinicaltrials.gov/>). The study has strictly met the requirements of the Declaration of Helsinki, and all the subjects will sign informed consent.
